Statement Regarding Recent Media Coverage

Basildon, UK, 3 June 2016 – Atnahs Pharma is providing the following statement in relation to recent media coverage.

Atnahs Pharma (“Atnahs”) is a UK registered limited company founded in 2013. The company makes and sells medicines both into the UK and internationally.

Atnahs acquires the rights to make medicines from large pharmaceutical companies at a significant upfront cost, once the medicines are no longer patented. As these medicines are no longer patented, other companies can also make these same medicines. After acquiring the rights, Atnahs then spends significant money on ensuring the medicines are in line with the latest regulatory, medical and technical standards.

For the medicines sold in the UK by Atnahs, it sells the vast majority through two wholesalers, AAH and Alliance Healthcare. These wholesalers then sell them to the NHS. The prices the NHS pays are negotiated on the open market and the NHS is the largest buyer of these medicines.

Atnahs generated revenue of £18.4 million in the UK for the calendar year ended 31 December 2015. The NHS spent £15.5 billion on generic medicines in 2014-2015.

The average sales price of a packet of Atnahs medicine in the UK was £18.20 in the same period, compared to the average branded medicine price in the UK of £20.95 and the current prescription charge of £8.40.

———————————————————————

Enquiries:
Ed Gascoigne-Pees / Hazel Stevenson
Camarco
0203 757 4984 / 89
ed.gascoigne-pees@camarco.co.uk / hazel.stevenson@camarco.co.uk